Core Viewpoint - Pomerantz LLP is investigating potential securities fraud and unlawful business practices involving Align Technology, Inc. and its officers or directors, following disappointing financial results and a significant stock price drop [1][3]. Financial Performance - Align Technology reported total revenues of approximately $1.01 billion for Q2 2025, which was below both consensus estimates and the company's own guidance [3]. - The company lowered its revenue guidance for Q3 and full-year growth expectations, attributing this to economic uncertainty and reduced demand for its products [3]. - Following the announcement, Align's stock price fell by $74.56 per share, or 36.63%, closing at $129.01 per share on July 31, 2025 [3]. Legal Investigation - Pomerantz LLP is actively investigating claims on behalf of investors regarding potential securities fraud by Align Technology [1]. - Investors are encouraged to contact Pomerantz LLP for more information about the investigation and potential class action [1].

Core Viewpoint - Align Technology, Inc. has filed a complaint under Section 337 of the Tariff Act, addressing issues of unfair competition related to the importation and sale of goods [1] Company Overview - Align Technology is a leading global medical device company specializing in the design, manufacture, and sale of the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry [1]

Financial Data and Key Metrics Changes - The company reported a 3.5% growth in the first half of the year, with expectations of normalizing to about 2.5% growth due to order timing adjustments [48][49] - For the second half, the company anticipates a growth rate of approximately 1.5%, normalizing to about 2.5% as well, aligning with the full-year guidance of 2% to 3% [49][50] - The purification and filtration divestiture is expected to provide a 25% to 30% annual benefit, with a significant portion of the EPS benefit realized in the fourth quarter [17][19] Business Line Data and Key Metrics Changes - The MedSurge business experienced a headwind in Q2 but is expected to accelerate in the second half, particularly in advanced wound care [49][50] - The dental segment has launched three new products this year, leading to strong traction and expectations for accelerated growth in the latter half of the year [36][38] Market Data and Key Metrics Changes - The company is focusing on attractive markets for innovation, leveraging its capabilities in material science and data science to drive growth [12][13] - The dental market is seeing a transformation with new product launches that are expanding market share and improving patient experience [38][39] Company Strategy and Development Direction - The company is undergoing a significant transformation in three phases: focusing on mission, talent, and culture; strategic alignment; and future transformation through portfolio rationalization [4][6] - The company aims to optimize its portfolio continuously, evaluating whether assets belong with them or should be divested [23][60] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving free cash flow guidance of $450 to $550 million despite a slow start in the first half due to timing issues [52][53] - For 2026, management anticipates tailwinds from commercial improvements and new product launches, while also acknowledging headwinds from SKU rationalization [55][56] Other Important Information - The company has made significant changes in leadership and talent within the MedSurge business to address past underperformance [14][15] - The partnership with Ensemble in revenue cycle management is expected to enhance the company's position in autonomous coding technology [42][46] Q&A Session Summary Question: How should we think about Q3 and Q4 in terms of cadence? - The company expects a normalization of growth rates in the second half, with specific improvements in advanced wound care and dental segments [49][50] Question: Can you talk about your confidence in achieving your free cash flow guidance? - Management is confident in meeting the guidance, with action plans in place to address the slow start in the first half [52][53] Question: What are your comments around valuations and the marketplace for tuck-in deals? - The company acknowledges that while attractive assets are not inexpensive, they will maintain a disciplined approach to acquisitions [35] Question: What are your expectations for pricing in 2025 and 2026? - The company expects pricing to be flat to plus 1%, focusing on sustainable volume growth rather than maximizing price [66][68]